Moving beyond traditional valuation of vaccination: Needs and opportunities

Bloom, David E.; Brenzel, Logan; Cadarette, Daniel; Sullivan, Jessica R.

doi:10.1016/j.vaccine.2016.12.001

Cited by 63 publications

(52 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35 Vaccines could prevent infectionseither sensitive or resistantand also reduce the use of antimicrobials, which in turn could slow the growth of AMR. [36][37][38][39][40][41][42][43][44][45][46] Child development benefits of vaccines Persistent or recurrent infections in early life can lead to poor growth and stunting, which in turn can adversely affect adult health, cognitive capacity, and economic productivity. [47][48][49] The theoretical basis of the long-term benefits of vaccines is anchored in the widely accepted "fetal origins" hypothesis 50,51 which links conditions in utero and during early childhood with later life outcomes.…”

Section: Economic Equity and Global Health Benefits Of Vaccinesmentioning

confidence: 99%

Why vaccines matter: understanding the broader health, economic, and child development benefits of routine vaccination

Nandi

Shet

2020

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The direct benefits of childhood vaccination in reducing the burden of disease morbidity and mortality in a cost-effective manner are well-established. By preventing episodes of vaccine-preventable diseases, vaccination can also help avert associated out-of-pocket medical expenses, healthcare provider costs, and losses in wages of patients and caregivers. Studies have associated vaccines positively with cognition and school attainment, suggesting benefits of long-term improved economic productivity. New evidence suggests that the measles vaccine may improve immunological memory and prevent coinfections, thereby forming a protective shield against other infections, and consequently improving health, cognition, schooling and productivity outcomes well into the adolescence and adulthood in lowincome settings. Systematically documenting these broader health, economic, and child development benefits of vaccines is important from a policy perspective, not only in low and middle-income countries where the burden of vaccine-preventable diseases is high and public resources are constrained, but also in high-income settings where the emergence of vaccine hesitancy poses a threat to benefits gained from reducing vaccine-preventable diseases. In this paper, we provide a brief summary of the recent evidence on the benefits of vaccines, and discuss the policy implications of these findings.

show abstract

Section: Economic Equity and Global Health Benefits Of Vaccinesmentioning

confidence: 99%

Why vaccines matter: understanding the broader health, economic, and child development benefits of routine vaccination

Nandi

Shet

2020

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Several economists have instead proposed the use of cost-benefit analysis (CBA) [7, 8]. The term CBA is often informally used to refer to any analysis used in decision-making that compares the expected costs and benefits (both in monetary terms) of an investment.…”

Section: Introductionmentioning

confidence: 99%

Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks

Park

Jit

2018

BMC Med

View full text Add to dashboard Cite

BackgroundThere is increasing interest in estimating the broader benefits of public health interventions beyond those captured in traditional cost-utility analyses. Cost-benefit analysis (CBA) in principle offers a way to capture such benefits, but a wide variety of methods have been used to monetise benefits in CBAs.MethodsTo understand the implications of different CBA approaches for capturing and monetising benefits and their potential impact on public health decision-making, we conducted a CBA of human papillomavirus (HPV) vaccination in the United Kingdom using eight methods for monetising health and economic benefits, valuing productivity loss using either (1) the human capital or (2) the friction cost method, including the value of unpaid work in (3) human capital or (4) friction cost approaches, (5) adjusting for hard-to-fill vacancies in the labour market, (6) using the value of a statistical life, (7) monetising quality-adjusted life years and (8) including both productivity losses and monetised quality-adjusted life years. A previously described transmission dynamic model was used to project the impact of vaccination on cervical cancer outcomes. Probabilistic sensitivity analysis was conducted to capture uncertainty in epidemiologic and economic parameters.ResultsTotal benefits of vaccination varied by more than 20-fold (£0.6–12.4 billion) across the approaches. The threshold vaccine cost (maximum vaccine cost at which HPV vaccination has a benefit-to-cost ratio above one) ranged from £69 (95% CI £56–£84) to £1417 (£1291–£1541).ConclusionsApplying different approaches to monetise benefits in CBA can lead to widely varying outcomes on public health interventions such as vaccination. Use of CBA to inform priority setting in public health will require greater convergence around appropriate methodology to achieve consistency and comparability across different studies.Electronic supplementary materialThe online version of this article (10.1186/s12916-018-1130-7) contains supplementary material, which is available to authorized users.

show abstract

“…This is specifically applicable to vaccination decisions. For example, the decision to be vaccinated against seasonal influenza weighs perception of individual risk of disease against the direct costs of the vaccination, the indirect costs of the time necessary to be vaccinated (lost opportunity), and any concerns about adverse vaccination effects [1] . The implications of individual vaccination in contributing to population immunity further complicates the decision.…”

Section: Introductionmentioning

confidence: 99%

Spatial and temporal risk as drivers for adoption of foot and mouth disease vaccination

Railey

Lembo

Palmer

et al. 2018

Vaccine

View full text Add to dashboard Cite

show abstract

Moving beyond traditional valuation of vaccination: Needs and opportunities

Cited by 63 publications

References 15 publications

Why vaccines matter: understanding the broader health, economic, and child development benefits of routine vaccination

Why vaccines matter: understanding the broader health, economic, and child development benefits of routine vaccination

Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks

Spatial and temporal risk as drivers for adoption of foot and mouth disease vaccination

Contact Info

Product

Resources

About